The global amyotrophic lateral sclerosis treatment market size was valued at USD 670 million in 2022. It is projected to reach USD 1,201.03 million by 2031, growing at a CAGR of 6.70% during the forecast period (2023-2031).
Amyotrophic lateral sclerosis (ALS), often known as Lou Gehrig's disease, is a neurodegenerative condition that progressively affects the nerve cells in the central nervous system regulating the voluntary muscles. Common symptoms include muscle twitching, stiffness, and weakness brought on by a reduction in the size of the muscles in the arms or legs. The ability to swallow, breathe, speak, walk, and use one's hands may be lost in almost half of ALS patients. The National Institute of Neurological Disorders and Stroke (NINDS) reports that persons with ALS frequently pass away from respiratory failure within three to five years after gradually losing their ability to breathe. It also notes that of the two forms of ALS. Sporadic ALS is the more prevalent variety, accounting for 90–95% of cases in the U.S., and familial ALS for the remainder.
Most individuals with Lou Gehrig's disease, also known as amyotrophic lateral sclerosis (ALS), pass away within 2-5 years of being diagnosed with this fatal neuromuscular condition. Typical ALS causes 5–10% of instances of ALS, a hereditary form of the illness, and unknown causes generate the remainder. All races and ethnicities are affected by ALS. However, the disease is more common in white people, men, non-Hispanics, those in their 60s, and those with a family history of it. An increasing incidence and prevalence of ALS are still being reported from various parts of the world, according to a review written by Longinetti and published in October 2019 that includes a summary of epidemiologic studies that looked at the incidence and risk factors for ALS and were published in the previous 18 months.
Amyotrophic lateral sclerosis is a fatal neurodegenerative condition. As a result, patients receive interdisciplinary care that frequently necessitates extensive utilization of medical resources. For various causes, including changes in ALS variables, the costs related to amyotrophic lateral sclerosis (ALS) may vary significantly. According to Erik Schönfelder, the mean annual cost of illness for each patient was estimated to be EUR 78,256 in the article titled "Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany," which was published in 2020. The lifetime cost per patient was estimated to be EUR 246,184. In Germany, the total annual burden was 519,776,352.
The population of adults above the age of 65 is steadily increasing. World Population Prospects estimates that by 2050, one in six of the world's population, up from one in eleven today, will be over 65. One in four people in Europe and North America could reach 65 years of age or older by 2050. For the first time in 2018, adults 65 and over outnumbered youngsters under the age of five worldwide. Age-related neurological conditions like amyotrophic lateral sclerosis (ALS), a chronic, deadly disease marked by the degradation of upper and lower motor neurons in the brain and spinal cord, are developing more frequently as the population ages. As a result, the market is rising as the population ages and the risk of ALS increases.
The global amyotrophic lateral sclerosis treatment market is segmented by treatment and distribution channel.
Based on treatment, the global amyotrophic lateral sclerosis treatment market is bifurcated into medication and others.
The medication segment is the highest contributor to the market and is estimated to grow at a CAGR of 6.45% during the forecast period. A fatal neuromuscular condition is called amyotrophic lateral sclerosis (ALS). Sporadic ALS and the familial form of the disease are the two different forms of ALS. The only two medications recognized by the FDA for the treatment of amyotrophic lateral sclerosis are Rilutek (riluzole) and Radicava (edaravone), even though there is no known cure for this disease. The U.S. Food and Drug Administration (FDA) approved the first medication to treat this illness in 1995 under Rilutek (riluzole). It is an oral formulation that slows the ALS symptoms' progression and lengthens survival. Numerous studies have shown that excessive quantities of the neurotransmitter glutamate harm the nerve cells that cause ALS.
Physical therapy, speech therapy, stem cell therapy, nutritional support, and respiratory support are some additional ALS treatment options. Stem cell-based therapy is a potential revolutionary therapeutic approach for ALS that is heavily researched and is likely to be effective. It might slow down the ALS patients' motor units' (M.U.s') progressive loss. Additionally, several studies are concentrating on how mesenchymal stem cell (MSC) Secretome can change illness. The Phase 3 pivotal trial of NurOwn (MSC-NTF cells) for amyotrophic lateral sclerosis' final participant dose was disclosed by BrainStorm Cell Therapeutics Inc. in June 2020. (ALS). An autologous MSC platform called NurOwn (MSC-NTF cells) aids in stimulating nerve tissue growth and enhances neuroprotective function.
Based on this, the global amyotrophic lateral sclerosis treatment market is bifurcated into hospital pharmacies, retail pharmacies, and others.
The hospital pharmacies segment owns the highest market and is estimated to grow at a CAGR of 7.20% during the forecast period. Around the world, several hospitals have separate departments that oversee all hospital-related purchases. Pharmaceuticals, medical supplies, equipment, and other items fall under this category. The pharmacy department is headed by several employees for pharmaceutical procurement, with assistance from a designated committee. Pharmaceutical corporations favor hospital pharmacies to ensure that needed medications are available as soon as possible. The significance of these services is unavoidable because the number of patients in the outpatient department is substantially higher during the day. Hospital pharmacies carry ALC drugs, including Rilutek (riluzole) and Radicava (edaravone).
An independent pharmacy with a state license to administer pharmaceuticals to the general public at retail pricing is referred to as a "retail pharmacy." These are only intended for direct consumer use; any hospital pharmacies, government pharmacies, or non-profit organizations receive the pharmaceuticals instead. The public is increasingly using the retail pharmacy in the current environment as a one-stop shop to purchase all over-the-counter and prescription goods. These retail pharmacies are considered one of the significant components of the distribution channel segment. Demand for this market is increased because a considerable portion of the expanding population cannot afford to visit hospitals frequently for checkups and urgently needs ALS prescription items.
Online pharmacies, clinics, and ALS centers are other alternative distribution channels that draw businesses and customers. Online pharmacies are one of the well-known distribution channels that have been extensively researched in developed markets and have been steadily embraced in emerging markets since the end of the previous decade. Due to society's increasing usage of the internet, the need for a wider variety of products on the internet has grown quickly. In addition, the growing popularity of eCommerce channels offering a wide range of products and in-depth drug information is driving segment growth. Moreover, clinics or ALS centers cover stem-based cell therapies and other therapies.
The global amyotrophic lateral sclerosis treatment market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant revenue contributor and is expected to grow at a CAGR of 6.55% during the forecast period. One of the economies with the most critical development is the United States. It presently controls a sizable portion of the market under investigation, and throughout the projected period, it is anticipated to maintain this trend. The rise of the senior population and the expanding patient base for Lou Gehrig's disease and amyotrophic lateral sclerosis are two major factors influencing the market in the United States. According to information on census.gov, there will be around 52,788 thousand Americans over 65 in 2019. As older people are more likely to develop neurodegenerative diseases like amyotrophic lateral sclerosis, the burden of these illnesses is also anticipated to rise as the country's population ages.
Asia-Pacific is expected to grow at a CAGR of 6.80% during the forecast period. The market for treating Amyotrophic Lateral Sclerosis in China is expanding steadily. The rising prevalence of ALS, the growing burden of the senior population, and the rising number of ALS-related research are the factors that are fueling the market's expansion in this region. According to a study titled "Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study," in 2016, China had an incidence rate of 1.65 per 100,000 people and a prevalence rate of 2.91 per 100,000 people. China is aging significantly more quickly than other low- and middle-income nations.
In Germany, the market is anticipated to expand primarily due to the increasing prevalence of amyotrophic lateral sclerosis and the growing elderly population. According to the source mentioned earlier, the onset's peak age was between 58 and 63 years old. As a result, this condition is more likely to be acquired by the growing elderly population. Approximately 83 million people live in Germany as of the present, according to the German Federal Statistical Office's 2020 report. In light of the above factors, a favorable market increase is anticipated over the forecast period.
The Brazilian market is anticipated to expand considerably during the forecast period. The main factors driving the expansion of the regional market are the rising prevalence of ALS disease, the rising elderly population, and disease awareness. This nation's aging population is growing, which is anticipated to support market expansion. Israel, Turkey, Iran, Iraq, Nigeria, Morocco, Kenya, Sudan, and other Sub-Saharan African (SSA) nations are among the other countries in the rest of the Middle East and Africa. The burden of amyotrophic lateral sclerosis disorders is rising in this area, along with the aging population and increased ALS awareness among the populace. These are some of the reasons driving market expansion in this area.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|